Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30119% above fair value
$43.65+0.41 (+0.95%)
Close on Nov 12, 2026Market cap $50.87BP/E 72.8Yield –
Teva Pharmaceutical Industries total assets
Total assets on the balance sheet at the end of each period.
Teva Pharmaceutical Industries's total assets was $39.86B at Jun 30, 2026. For fiscal 2025 it was $40.75B, up 3.6% from the year before. Over ten years it grew -2.8% a year on average. The highest annual figure on record is $93.06B in fiscal 2016.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.75B | +3.6% |
| FY2024 | Dec 31, 2024 | $39.33B | -9.6% |
| FY2023 | Dec 31, 2023 | $43.48B | -1.2% |
| FY2022 | Dec 31, 2022 | $44.01B | -7.7% |
| FY2021 | Dec 31, 2021 | $47.67B | -5.9% |
| FY2020 | Dec 31, 2020 | $50.64B | -11.9% |
| FY2019 | Dec 31, 2019 | $57.47B | -5.3% |
| FY2018 | Dec 31, 2018 | $60.68B | -14.1% |
| FY2017 | Dec 31, 2017 | $70.62B | -24.1% |
| FY2016 | Dec 31, 2016 | $93.06B | +71.6% |
| FY2015 | Dec 31, 2015 | $54.23B | +16.8% |
| FY2014 | Dec 31, 2014 | $46.42B | -2.3% |
| FY2013 | Dec 31, 2013 | $47.51B | -6.1% |
| FY2012 | Dec 31, 2012 | $50.61B | +0.9% |
| FY2011 | Dec 31, 2011 | $50.14B | +31.4% |
| FY2010 | Dec 31, 2010 | $38.15B | +14.9% |
| FY2009 | Dec 31, 2009 | $33.21B | +0.9% |
| FY2008 | Dec 31, 2008 | $32.92B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $39.86B | -0.7% |
| Q1 FY2026 | Mar 31, 2026 | $40.04B | +4.2% |
| Q4 FY2025 | Dec 31, 2025 | $40.75B | +3.6% |
| Q3 FY2025 | Sep 30, 2025 | $39.86B | -4.6% |
| Q2 FY2025 | Jun 30, 2025 | $40.13B | -2.9% |
| Q1 FY2025 | Mar 31, 2025 | $38.42B | -10.2% |
| Q4 FY2024 | Dec 31, 2024 | $39.33B | -9.6% |
| Q3 FY2024 | Sep 30, 2024 | $41.76B | -0.8% |
| Q2 FY2024 | Jun 30, 2024 | $41.34B | -4.1% |
| Q1 FY2024 | Mar 31, 2024 | $42.77B | -1.6% |
| Q4 FY2023 | Dec 31, 2023 | $43.48B | -1.2% |
| Q3 FY2023 | Sep 30, 2023 | $42.10B | -4.9% |
| Q2 FY2023 | Jun 30, 2023 | $43.10B | -6.2% |
| Q1 FY2023 | Mar 31, 2023 | $43.46B | -7.6% |
| Q4 FY2022 | Dec 31, 2022 | $44.01B | -7.7% |
| Q3 FY2022 | Sep 30, 2022 | $44.25B | -7.5% |
| Q2 FY2022 | Jun 30, 2022 | $45.93B | -6.6% |
| Q1 FY2022 | Mar 31, 2022 | $47.06B | -4.0% |
| Q4 FY2021 | Dec 31, 2021 | $47.67B | -5.9% |
| Q3 FY2021 | Sep 30, 2021 | $47.85B | -3.8% |
| Q2 FY2021 | Jun 30, 2021 | $49.20B | -10.5% |
| Q1 FY2021 | Mar 31, 2021 | $49.00B | -11.4% |
| Q4 FY2020 | Dec 31, 2020 | $50.64B | -11.9% |
| Q3 FY2020 | Sep 30, 2020 | $49.74B | -13.1% |
| Q2 FY2020 | Jun 30, 2020 | $54.99B | -7.5% |
| Q1 FY2020 | Mar 31, 2020 | $55.33B | -7.6% |
| Q4 FY2019 | Dec 31, 2019 | $57.47B | -5.3% |
| Q3 FY2019 | Sep 30, 2019 | $57.25B | -12.0% |
| Q2 FY2019 | Jun 30, 2019 | $59.42B | -11.3% |
| Q1 FY2019 | Mar 31, 2019 | $59.85B | -13.5% |
| Q4 FY2018 | Dec 31, 2018 | $60.68B | -14.1% |
| Q3 FY2018 | Sep 30, 2018 | $65.06B | -24.4% |
| Q2 FY2018 | Jun 30, 2018 | $67.03B | -22.4% |
| Q1 FY2018 | Mar 31, 2018 | $69.18B | -24.2% |
| Q4 FY2017 | Dec 31, 2017 | $70.62B | -24.1% |
| Q3 FY2017 | Sep 30, 2017 | $86.08B | -12.8% |
| Q2 FY2017 | Jun 30, 2017 | $86.36B | – |
| Q1 FY2017 | Mar 31, 2017 | $91.28B | – |
| Q4 FY2016 | Dec 31, 2016 | $93.06B | – |
| Q3 FY2016 | Sep 30, 2016 | $98.75B | – |
See a number that looks wrong?